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respectively. There was no discernible change in the levels or switching of the Ig-isotypes
over a 6m clinical course. However, independent of the study group, baseline levels of
IgG3 were significantly lower (vs blood donors [BD]) in pts (n=23) who subsequently had
improvement in NYHA-fc by at least one class at follow-up vs non-improvers (n=48);
0.139 (0.084-0.308) vs 0.326 (0.103-0.537) respectively (p=0.02). IgG3 levels in the non-
improvers were significantly higher compared to BD at baseline and 6m. Mortality, hosp
and adverse events were greater in pts who did not improve in NYHA-fc. Levels of Ig-Gt,
G1, G2, TNF-α, IFN-γ, IL-6 or IL-10 did not discriminate fc at follow-up. The data sug-
gests that the effects of IMT are not mediated by modulation of Ig-responses. However
and importantly the findings further support the prognostic and potentially pathological
role of raised levels of cardiac specific G3-Igs in HF.
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Background: Patients with hypertensive left ventricular (LV) hypertrophy often have sys-
tolic and diastolic LV dysfunction. Doppler echocardiography allows assessment of the
myocardial performance index (MPI=[isovolumic relaxation and contraction time]/[aortic
ejection time]) as a global estimate of LV function. The aim of this study was to determine
the prognostic importance of MPI in a large hypertensive population with LV hypertrophy.
Methods: A total of 960 prospectively identified patients with essential hypertension and
evidence of LV hypertrophy on a screening electrocardiogram had echocardiograms at
enrolment in the Losartan Intervention For Endpoint prevention in hypertension (LIFE)
trial, of whom 741 with MPI measurements at baseline were followed a mean of 4.8 years
for a composite endpoint of cardiovascular (CV) morbidity and mortality (CV death,
stroke and myocardial infarction)..
Results: During the follow-up period 78 patients suffered composite endpoints, 21 suf-
fered CV death, 47 had fatal or non-fatal stroke and 29 had fatal or non- fatal myocardial
infarction. In Cox regression models controlling for differences in treatment type, baseline
LV mass index and systolic blood pressure, there was a strong association between (per
unit) higher MPI and increased rate of the composite cardiovascular endpoint (HR=3.10,
95% CI=1.42-6.77, p=0.005). There were parallel associations between higher MPI and
stroke (HR=2.32, 95% CI=1.04-5.16, p=0.04) and myocardial infarction (HR=3.86, 95%
CI=1.18-12.57, p=0.025) but CV mortality was not associated with the MPI. Furthermore,
in a combined model higher MPI independently predicted the composite endpoint
(HR=1.38 95%CI=1.12-1.70, p=0.002) when taking midwall fractional shortening
(HR=0.65 95% CI=0.52-0.82) and mitral valve deceleration time (HR=1.23 95%
CI=1.001-1.52, p=0.048) into account
Conclusions: In hypertensive patients with ECG LV hypertrophy the MPI index has
important prognostic value independent of blood pressure, treatment and other systolic
and diastolic LV functional parameters.
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Background:
Increased plasma homocysteine (HCY) levels are associated with increased risk of vas-
cular disease. Whether or not HCY affects the development of congestive heart failure
(CHF) independent of coronary artery disease (CAD) is uncertain. We evaluated whether
increased HCY predicts low ejection fraction (EF) or clinical CHF.
Methods:
A total of 2,842 consecutive consenting patients who underwent coronary angiography
and EF determination and a fasting plasma HCY level measured between 1994-1999
were prospectively studied. Left ventricular dysfunction (LVD) was defined as EF <40%.
HCY was measured by fluorescence polarization immunoassay. Multivariable logistic
regressions were performed to assess the predictive value for LVD or LVD/CHF of HCY
and 13 other variables, including renal insufficiency.
Results:
Age averaged 64+12 y; 69% were men; 74% had CAD; 12%, LVD; and 21.9%, LVD or
clinical CHF. Quartiles (Q) of HCY overall were: < 10.5, 10.5-13.2, 13.3-17.0 and > 17.1
µmol/L. LVD and LVD/CHF were more prevalent in Q3 (15%, 25%) and Q4 (15%, 27%)
than Q1 HCY (8.4%, 18%, p<0.001 vs Q4). After adjustment for baseline variables, clini-
cal presentation, and C-reactive protein, Q3 or Q4 HCY independently predicted LVD
(odds ratio [OR]=1.7 [CI, 1.2-2.5], p=0.004; OR=1.8 [CI, 1.3-2.6], p=0.002) or LVD/CHF
(OR=1.4, p=0.03 [CI, 1.04-1.8]; OR=1.7 [CI, 1.3-2.2], p<0.001). Findings did not differ by
disease etiology: relative risk for LVD (OR=1.7) and LVD/CHF (OR=1.7) for Q4 HCY
among patients free from CAD was similar to the overall population and those with CAD.
Further, there was no interaction of results with gender.
Conclusion:
High plasma HCY level (Q3/4, >13.3 µmol/L) is a strong predictor of LVD or the combined
endpoint of LVD/clinical CHF. This relationship is independent of CHF etiology (ischemic
versus non-ischemic) and gender, as well as 11 other variables. Because results are con-
sistent with either a causal (e.g., HCY-induced myocardial and vascular injury) or non-
causal mechanism (e.g., secondary to CHF-associated renal hypoperfusion, although
adjustment was made for renal insufficiency), further research is indicated.
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Background: Patients hospitalized with acute pulmonary edema have a high rate of
reoccurrence and mortality. Factors that predict readmission or mortality in this patient
population have not been determined. We hypothesize that Echo-Doppler and clinical
data can define a high risk in patients admitted with acute pulmonary edema.
Methods: In 85 patients admitted with acute pulmonary edema, we evaluated clinical
characteristics and Echo-Doppler parameters determined after treatment to determine
predictors for reoccurrence and mortality. Doppler mitral flow pattern was used to classify
the grade of diastolic dysfunction. Up to 3.5 years follow up (mean = 22 months) was
obtained on 82 patients (96%).
Results: The two-year survival was 78%. Survival free of recurrent pulmonary edema
was 63% at six months, 54% at one year, and 41% at two years. There was no difference
in reoccurence-free survival based on ejection fraction, coronary artery disease, gender,
age, admitting blood pressure, or discharge medications. The prognosis was related to
severity of diastolic dysfunction. Patients with a normal filling pattern had a 100% two-
year survival and 60% two-year reoccurrence-free survival. In contrast, patients with a
restrictive pattern had only a 44% two-year survival and 36% two-year reoccurrence-free
survival (p<0.05). Patients with impaired relaxation and pseudo-normal filling had inter-
mediate two-year survival (88% and 65%, respectively). Anemia (Hgb<11 gm/dl) was
associated with a lower two-year survival (68% vs 80%) and reduced reoccurrence-free
survival (20% vs 47%) (p<0.05). Similarly, creatinine > 2.4 (mg/dl) was associated with
worse reoccurrence-free survival (20% vs 47%) (p<0.05).
Conclusion: Patients admitted with acute pulmonary edema have a high reoccurrence
rate (46% at 12 months). The degree of diastolic dysfunction by mitral Doppler, anemia,
and renal insufficiency are associated with a worse prognosis.
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Background: Highly sensitive C-reactive protein (hsCRP), a marker of inflammation, is a
strong predictor of cardiovascular events in coronary artery disease. However, the role of
CRP in heart failure (HF) has not been extensively studied. Valsartan Heart Failure Trial
(Val-HeFT) provided an opportunity to examine this in patients with moderate to severe
HF. Methods: Plasma hsCRP (mg/L) was measured by a nephelometric analyzer (Dade
Behring) in core labs at baseline (BL), and during follow-up in over 4000 patients. Cox
proportional hazards and log-rank analyses were made for all-cause mortality and sub-
sequent first morbid event with baseline CRP classification by median (> or < 3.23 mg/L)
and quartile (Q) groupings used as independent variables in separate analyses. Results:
BL mean (±SD) CRP was elevated at 6.45±10.06 mg/L (n=4202, median 3.23 mg/L) as
compared to healthy controls (median 1.5 mg/L), and was higher in patients with more
advanced HF (p<0.05). BL CRP was a significant independent predictor of mortality and
first morbid event when analyzed both as dichotomized (mortality: RR 1.18, 95% CI, 1.01
to 1.38, p=0.032; first morbid event: RR 1.15, 95% CI 1.02 to 1.31, p=0.027 and quartile
variables (p<0.00001 for mortality, Figure). Conclusions: Patients with moderate to
severe HF have high circulating hsCRP, which is a significant independent predictor of
mortality and morbidity in patients with moderate to severe HF. These data suggest that
inflammation may have a role in the progression of HF.
